Answers are grounded in this paper and cite their sources.
Enzalutamide resistance is the principal cause of treatment failure in advanced prostate cancer. Aberrant vasculature and glycolytic reprogramming are implicated, but human evidence linking them remains fragmented. In this observational computational study, we profiled enzalutamide-resistant C4-2B cells (GSE64143), 497 TCGA-PRAD primary tumors and 266 metastatic castration-resistant prostate cancer (mCRPC) samples (SU2C/PCF, pooled abiraterone and enzalutamide exposure), with validation in the MSKCC and GSE70768 cohorts, protein-level data and metastatic single-cell RNA sequencing (GSE297652). In resistant cells, hypoxia and glycolysis were the top activated programs while androgen response was suppressed. Hypoxia, glycolysis and angiogenesis scores were strongly coupled in primary tumors but predicted overall survival only in mCRPC (glycolysis HR = 11.7), defining a boundary condition: this axis is prognostic only in treated, advanced disease. Network-pharmacology analysis positioned the Qi-Bi-Yin (QBD) target HIF1A within this axis, and bidirectional in silico perturbation indicated that BCL2 and HIF1A differentially influence axis integrity. Connectivity-map screening and ChEMBL bioactivity mining nominated candidate compounds for experimental follow-up (e.g. the NAMPT inhibitor FK-866; formononetin–BCL2 Ki = 10 nM). Taken together, these observational findings point to a metabolic–vascular coupling axis and suggest potential therapeutic targets requiring experimental validation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: